Oligonucleotides, Antisense
"Oligonucleotides, Antisense" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Short fragments of DNA or RNA that are used to alter the function of target RNAs or DNAs to which they hybridize.
MeSH Number(s)
D13.150.480
D13.444.600.150.640
D13.695.578.424.480
D27.720.470.530.600.150.640
Concept/Terms
Oligonucleotides, Antisense- Oligonucleotides, Antisense
- Antisense Oligonucleotides
- Anti-Sense Oligonucleotides
- Anti Sense Oligonucleotides
- Oligonucleotides, Anti-Sense
Below are MeSH descriptors whose meaning is more general than "Oligonucleotides, Antisense".
Below are MeSH descriptors whose meaning is more specific than "Oligonucleotides, Antisense".
This graph shows the total number of publications written about "Oligonucleotides, Antisense" by people in Harvard Catalyst Profiles by year, and whether "Oligonucleotides, Antisense" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 12 | 13 |
| 1994 | 2 | 6 | 8 |
| 1995 | 5 | 7 | 12 |
| 1996 | 9 | 6 | 15 |
| 1997 | 6 | 6 | 12 |
| 1998 | 8 | 2 | 10 |
| 1999 | 4 | 5 | 9 |
| 2000 | 4 | 9 | 13 |
| 2001 | 3 | 6 | 9 |
| 2002 | 3 | 9 | 12 |
| 2003 | 1 | 24 | 25 |
| 2004 | 4 | 8 | 12 |
| 2005 | 2 | 16 | 18 |
| 2006 | 2 | 9 | 11 |
| 2007 | 2 | 2 | 4 |
| 2008 | 0 | 4 | 4 |
| 2009 | 1 | 11 | 12 |
| 2010 | 0 | 6 | 6 |
| 2011 | 2 | 6 | 8 |
| 2012 | 3 | 6 | 9 |
| 2013 | 2 | 6 | 8 |
| 2014 | 4 | 4 | 8 |
| 2015 | 1 | 5 | 6 |
| 2016 | 4 | 5 | 9 |
| 2017 | 5 | 4 | 9 |
| 2018 | 7 | 5 | 12 |
| 2019 | 7 | 4 | 11 |
| 2020 | 7 | 5 | 12 |
| 2021 | 7 | 2 | 9 |
| 2022 | 4 | 5 | 9 |
| 2023 | 0 | 1 | 1 |
Below are the most recent publications written about "Oligonucleotides, Antisense" by people in Profiles.
-
Unlocking the potential of chemically modified peptide nucleic acids for RNA-based therapeutics. RNA. 2023 Apr; 29(4):434-445.
-
Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1 Exon Skipping Antisense Oligonucleotides. Nucleic Acid Ther. 2023 01; 33(1):17-25.
-
CNS Delivery of Nucleic Acid Therapeutics: Beyond the Blood-Brain Barrier and Towards Specific Cellular Targeting. Pharm Res. 2023 Jan; 40(1):77-105.
-
Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2022 09 22; 387(12):1099-1110.
-
Angiotensinogen: More Than its Downstream Products: Evidence From Population Studies and Novel Therapeutics. JACC Heart Fail. 2022 10; 10(10):699-713.
-
An intranasal ASO therapeutic targeting SARS-CoV-2. Nat Commun. 2022 08 03; 13(1):4503.
-
Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides. Proc Natl Acad Sci U S A. 2022 07 19; 119(29):e2113180119.
-
Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study. Neurotherapeutics. 2022 07; 19(4):1248-1258.
-
Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers. Nature. 2022 03; 603(7900):335-342.
-
Targeting stem-loop 1 of the SARS-CoV-2 5' UTR to suppress viral translation and Nsp1 evasion. Proc Natl Acad Sci U S A. 2022 03 01; 119(9).